Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069709 | 0.82 | SSTR1 (0.42) | RETKDM5ASMN1; SMN2CCR2SSTR1 | |
| SCHEMBL20147503 | 0.78 | KDM5A (0.38) | RETKDM5ACCR2SSTR1SSTR4 | |
| SCHEMBL20147927 | 0.76 | KDM5A (0.37) | RETKDM5ACCR2 | |
| SCHEMBL21651943 | 0.72 | CHRNB4 (0.38) | RETEPHX1EPHX2SMN1; SMN2UBE2M | |
| SCHEMBL20158500 | 0.72 | RET (0.40) | RETKDM5AEPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL2190589 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL2190593 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL2190586 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL20069725 | 0.65 | RET (0.40) | RETKDM5ASSTR1SSTR4DRD2 | |
| SCHEMBL23475172 | 0.65 | SMN1; SMN2 (0.42) | SMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885KDM5A 902/4885EPHX1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.